Design, synthesis, and biological evaluation of aromatic ester prodrugs of 1-(3'-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41) as orally active iron chelators

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 5, 2000, Pages 461-470

  Liu, Zu D ^a   Liu, Ding Y ^a   Lu, Shu L ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

1 (3' hydroxypropyl) 2 methyl 3 hydroxypyridin 4 one; CP41; Hydroxypyridinone, aromatic ester prodrugs, in vivo studies, rat, synthesis; Iron chelators

Indexed keywords

3 HYDROXY 1 (3 HYDROXYPROPYL) 2 METHYL 4 PYRIDINONE; CHELATING AGENT; DEFERIPRONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHELATION; CONTROLLED STUDY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG SYNTHESIS; IRON OVERLOAD; IRON TRANSPORT; MALE; NONHUMAN; RAT;

EID: 0034035958     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300231     Document Type: Article

References (19)

1. [1] Tilbrook, G. S., Hider, R. C., Iron Chelators for clinical use. In: Metal Ions in Biological Systems, Vol. 35, A. Sigel, H. Sigel (eds.), pp. 691-730, Marcel Dekker, New York, (1998)
2. [2] Brittenham, G. M., Development of iron-chelating agents for clinical use. Blood, 80, 569 (1992)
3. [3] Singh, S., Epemolu, O., Dobbin, P. S. et al., Urinary metabolic profiles in man and rat of 1,2-dimethyl-and 1,2-diethyl substituted 3-hydroxypyridin-4-ones. Drug Metab. Dispos. 20, 256 (1992)
4. [4] Singh, S., Epemolu, R. O., Ackerman, R. et al., Development of 3-hydroxypyridin-4-ones which do not undergo extensive phase II metabolism, 3rd NIH-Sponsored Symposium on The Development of Iron Chelators for Clinical Use. Gainsville, FL, Abstract 52 (1992)
5. [5] Singh, S., Choudhury, R., Epemolu, R. O. et al., Metabolism and pharmacokinetics of 1-(2'-hydroxyethyl-and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat. Eur. J. Drug Metab. Pharmacokinet. 21, 33 (1996)
6. [6] Zanninelli, G., Choudury, R., Loreal, O. et al., Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats. J. Hepatol. 27, 176 (1997)
7. [7] Rai, B. L., Dekhordi, L. S., Khodr, H. et al., Synthesis, Physicochemical properties and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. J. Med. Chem. 41, 3347 (1998)
8. [8] Liu, Z. D., Liu, D. Y., Lu, S. L. et al., Synthesis, Physicochemical Properties and Biological Evaluation of Aromatic Ester Prodrugs of 1-(2'-Hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): Orally Active Iron Chelators with Clinical Potential. J. Pharm. Pharmacol. 51, 555 (1999)
9. [9] Choudhury, R., Epemolu, R. O., Rai, B. L. et al., Metabolism and pharmacokinetics of 1-(2'-trimethyl-acetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. Drug Metab. Dispos. 25, 332 (1997)
10. [10] Lu, S. L., Liu, D. Y., Gosriwatana, I. et al., In-vivo metabolism of 1-(3'-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41) and 1-(2'-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102) by rat. J. Pharm. Pharmacol. 50, 199 (1998)
11. [11] Moerker, T., Peter, H., United States Patent No. 4,908,371 (1990)
12. [12] Fessenden, R. J., Fessenden, J. S., Organic Chemistry, 4th Ed., pp. 1008-1009, Books/Cole Publishing Company, Monterey, California (1990)
13. [13] Holme, E., Greter, J., Jacobson, C. E. et al., Carnitine deficiency induced by pivampicillin and pivampicillinam therapy. Lancet 469 (1989)
14. [14] Holme, E., Jodal, U., Linstedt, S. et al., Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children. Scand. J. Clin. Invest. 52, 361 (1992)
15. [15] Melegh, B., Kerner, J., Bieber, L. L., Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem. Pharmacol. 36, 3405 (1987)
16. [16] Dobbin, P. S., Hider, R. C., Hall, A. D. et al., Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: Orally active iron chelators with clinical potential. J. Med. Chem. 36, 2448 (1993)
17. 59Feferritin loaded rat model. Biochem. Pharmacol. 57, 559 (1999)
18. [18] Mitsunobu, O., The use of diethylazodicarboxylate and triphenylphosphine in synthesis and transformation of nature products. Synthesis 1, 1 (1981)
19. [19] Pippard, M. J., Johnson, D. K., Finch, C. A., A rapid assay for evaluation of iron chelating agents in rats. Blood 58, 685 (1981)